Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies (NCT04764396) | Clinical Trial Compass
TerminatedNot Applicable
Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies
Stopped: Lack of funding and change in research direction.
United States2 participantsStarted 2021-03-12
Plain-language summary
This is a randomized study that will enroll patients scheduled for an endoscopic ultrasound biopsy of a pancreas lesion to be in the heparin or saline group during the procedure.
The purpose of this study is to examine the effect of blood contamination, heparin priming of the fine needle biopsies, and pass number on tumor tissue quality in fine needle biopsies.
The hypothesis for this study is that fine needle biopsy tissue quality of pancreatic masses decreases with increasing pass number due to blood contamination; this blood contamination can be ameliorated with priming of the needle with an anticoagulant such as heparin.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient identified as having a possible solid pancreatic lesion on computed tomography or magnetic resonance
* Patient scheduled for Endoscopic ultrasound (EUS) for sampling of pancreatic mass
Exclusion Criteria:
* known history of coagulopathy
* history of heparin allergy
* patients with evidence of vascular tumors on imaging
* Patients with history of chronic pancreatitis
* Pregnant patients
* Medically unstable patients
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Cellularity Captured in Fine Needle Biopsies for the Heparin Group
Timeframe: Day 1 (biopsy tissue obtained)
2
Blood Contamination in Fine Needle Biopsies for the Heparin Group